J.P. Morgan discloses Kangji Medical share dealings during privatisation

On September 17, 2025, the Executive received a disclosure of securities dealings from J.P. Morgan Securities PLC concerning Kangji Medical Holdings Limited, which is being privatised via a scheme of arrangement. The dealings, made on September 16, 2025, involved the purchase of 88,500 shares.

These purchases, categorised as "other types of securities" (e.g., equity swaps), involved the hedging of Delta 1 products resulting from unsolicited client-driven orders. The total amount paid was $787,225.2000, with both the highest and lowest prices paid/received recorded at $8.8952 per share.

J.P. Morgan Securities PLC, a Class (5) associate connected with the Offeror and ultimately owned by JPMorgan Chase & Co., confirmed that these dealings were executed for its own account.